Chimerix, Inc. (CMRX) NASDAQ
8.54
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
8.54
+0(+0.00%)
Currency In USD
| Previous Close | 8.54 |
| Open | 8.54 |
| Day High | 8.54 |
| Day Low | 8.54 |
| 52-Week High | 8.55 |
| 52-Week Low | 0.75 |
| Volume | 2.55M |
| Average Volume | 4.05M |
| Market Cap | 801.08M |
| PE | -8.63 |
| EPS | -0.99 |
| Moving Average 50 Days | 6.67 |
| Moving Average 200 Days | 2.75 |
| Change | 0 |
Data not available
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
GlobeNewswire Inc.
Mar 05, 2025 12:00 PM GMT
-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- -Transaction to add near-term commercial opportunity to Jazz’s pipeline- -Transaction represents total cash consideration of approximately $935
Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma
GlobeNewswire Inc.
Feb 18, 2025 12:00 PM GMT
Potential First Approval for Patients with Recurrent H3 K27M-mutant Diffuse Glioma PDUFA Target Action Date of August 18, 2025 No Advisory Committee Meeting Currently Planned to Discuss Application DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- C
Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium
GlobeNewswire Inc.
Jan 29, 2025 9:15 PM GMT
DURHAM, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mi